Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001213900-25-075307·BridgeBio Oncology Therapeutics, Inc.
Schedule 13D ownership disclosure
BridgeBio Oncology Therapeutics Inc
Common Stock · CUSIP: 107924102
Event date: 2025-08-11
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Helix Holdings II LLCReported CIK 0001869101
Shares: 4,528,186.00 · Class: 5.7%
- Cormorant Global Healthcare Master Fund, LPReported CIK 0001618442
Shares: 5,952,356.00 · Class: 7.5%
- Cormorant Global Healthcare GP, LLCReported CIK 0001618451
Shares: 5,952,356.00 · Class: 7.5%
- Bihua ChenReported CIK 0001599214
Shares: 17,878,594.00 · Class: 22.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-25-075307
- Form type
- SCHEDULE 13D/A
- Filer
- BridgeBio Oncology Therapeutics, Inc.
- CIK
- CIK 1869105
- Filed
- Aug 13, 2025
- Reporting period
- Aug 11, 2025
- Description
- Schedule 13D beneficial ownership